Discover a study that explores how PARP inhibition with niraparib may offer new therapeutic potential for advanced melanoma ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Unlike ATR, the ATM inhibitor-mediated decrease in pS6K is dependent on the TSC complex (Fig. 1G). Together, these data demonstrate a link between the DDR and mTORC1 signaling in unperturbed cells and ...

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure hospitalization, regardless of diabetes status.

ATM inhibition exacerbated AP site accumulation, leading to genotoxic stress diffusion, cell cycle dysregulation, and mitotic catastrophe. In vitro, combining ATM inhibitors with RAI significantly ...

Here we demonstrate that the treatment of intracellular tachyzoites with the PI3K inhibitor caffeine or ATM kinase-inhibitor KU-55933 affects parasite replication rate in a dose-dependent manner.

Combined HDAC and ATM inhibition potentiates anticancer effects in glioblastoma preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial that multiple experts are calling practice changing.

ATM inhibitors (ATMi) are potent radiosensitizers in colorectal cancer (CRC). Proton irradiation exhibits an entrance portion of the beam (ENT) where dose is deposited sparsely and a Bragg Peak (BP) ...

A pivotal finding of this research is the synthetic lethal effect when BEND4 expression is lost in combination with ATM inhibitor treatment. The study showed that PDAC cells with BEND4 methylation ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1.